Tengion CEO Nichtberger resigns
Dr. Steven A. Nichtberger has resigned as president and CEO of Tengion, a regenerative medicine company focused on developing replacement organs and tissues grown from a person’s own cells, according to a report in the Philadelphia Business Journal.
Nichtberger is also stepping down from the company’s board of directors.
“I am pleased that as I leave my role at Tengion, the company is positioned to pursue the advancement of its organ regeneration platform and I wish Tengion success in bringing its product candidates to patients in need,” said Nichtberger in a statement released by the company.
Tengion of East Norriton, Pa., said David I. Scheer, the company’s board chairman, will assume a more active role in guiding the company while an external search is conducted for a new chief executive officer.
Nichtberger was at the helm at Tengion earlier this year when the company’s dwindling cash flow problem was resolved through a $31.4 million private stock sale.
Tengion reaffirmed its plan to submit next quarter to the FDA additional clinical data and modifications to the surgical approach for its experimental Neo-Urinary Conduit product.
The company also reiterated its plans to request a meeting with the FDA by the end of this year to discuss its plan for conducting clinical trials for its Neo-Kidney Augment product, which is intended to prevent or delay the need for dialysis or kidney transplant by increasing functional kidney mass in patients with advanced chronic kidney disease.
Upcoming Events
-
23Apr
-
07May
-
14May